Loading...

LGVN LONGEVERON INC US FDA Inspections 8-K Filing

LNGV

LGVN

LONGEVERON INC

(LGVN)

2025 8-K

Nasdaq Compliance Update

Stockholder Meeting Cancell...

Capital Raise Announcement

Director Resignation

Leadership Change

Director Resignations

Financial Results Update

Board Appointment

Nasdaq Compliance Notice

ATM Offering Agreement

Financial Results Update

Clinical Trials

Financial Statements

Cash-to-Equity Program

Financial Results

Board Resignation

Financial Results

Earnings Announcement

Securities Purchase Agreement

FDA Designation for Lomecel...

Annual Meeting of Stockholders

Inducement Transaction

Resignation and Appointment...

Warrant Exercise and Issuan...

Public Offering

Reverse Stock Split

Special Meeting Approval

Meeting Approval

Securities Purchase Agreement

Securities Purchase Agreement

Rights Offering

Dealer-Manager Agreement fo...

Rights Offering Announcement

Annual Meeting Results

Departure of CFO

Earnings Reports

Financial Results Announcement

Appointment of CEO

Compensation Increase

External Links:

On July 8, 2025, Longeveron Inc. announced that the FDA cleared their IND application for a Phase 2 clinical trial of laromestrocel, a potential treatment for pediatric dilated cardiomyopathy.

AI Assistant

LONGEVERON INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.